Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel - Bristol-Myers Squibb

Drug Profile

Paclitaxel - Bristol-Myers Squibb

Alternative Names: BMS-181339; BMY 45622; NSC-673089; Taxol

Latest Information Update: 27 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Bristol-Myers Squibb; University of Washington
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer
  • Phase II Head and neck cancer
  • Discontinued Bladder cancer; Cancer metastases; Cervical cancer; Endometrial cancer; Leukaemia; Lung cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Pleural effusion; Prostate cancer; Sarcoma; Small cell lung cancer; Testicular cancer

Most Recent Events

  • 08 May 2017 Bristol-Myers Squibb terminates a phase I/II trial as the sponsor withdrew the study in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT00041470)
  • 30 May 2013 Biomarkers information updated
  • 17 Mar 2005 Registered as adjuvant treatment for early stage node-positive breast cancer in European Union under the mutual recognition procedure; the Netherlands acted as the reference member state (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top